AFib for Professionals

The prevalence of AFib in the United States (US) is estimated to rise from ≈5.2 million in 2010 to 12.1 million in 2030. Data from a health insurance claims database covering 5% of the US found the incidence of AFib was estimated at 1.2 million new cases in 2010 and projected it to increase to 2.6 million new cases in 2030. The lifetime risk of AFib in the US is about ≈1 in 3 in Whites and ≈1 in 5 in Blacks. Even with current guideline-based management, AFib patients have stroke, acute coronary syndrome, heart failure, and cardiovascular death at a rate of approximately 5% of patients per year, and 35 to 50% of patients with AFib who receive adequate anticoagulation either receive inpatient therapy or die within 5 years.